Page last updated: 2024-11-04

demecarium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

demecarium: major descriptor (65-85); on-line search AMMONIUM COMPOUNDS (66-85); Index Medicus search DEMECARIUM BROMIDE (65-85) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

demarcarium : The bis(quaternary ammonium) dication obtained by N,N'-dimethylation of the N,N'-bis[3-(dimethylamino)phenyl carbamate] derivative of 2,13-diazatetradecane. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5966
CHEMBL ID1201229
CHEBI ID59719
SCHEMBL ID61421
MeSH IDM0424412

Synonyms (32)

Synonym
BPBIO1_000608
NCGC00179526-01
PRESTWICK3_000616
BSPBIO_000552
AB00513869
demecarium
DB00944
demecarium cation
demecarium ion
CHEBI:59719 ,
3,3'-{decane-1,10-diylbis[(methylcarbamoyl)oxy]}bis(n,n,n-trimethylanilinium)
demarcarium
CHEMBL1201229
3,3'-(1,10-decanediylbis((methylimino)carbonyloxy))bis(n,n,n-trimethylbenzenaminium)
demecarium [who-dd]
ilp8xj8r5k ,
unii-ilp8xj8r5k
16505-84-3
n,n'-bis(3-trimethylammoniumphenoxycarbonyl(-n,n'-dimethyldecamethylenediamine
demecarium [vandf]
(m-hydroxyphenyl)trimethylammonium decamethylenebis(methylcarbamate)
benzenaminium, 3,3'-(1,10-decanediylbis((methylimino)carbonyloxy))bis(n,n,n-trimethyl-
SCHEMBL61421
DTXSID2046965 ,
NCGC00179526-03
n,n,n-trimethyl-3-{[methyl(10-{methyl[3-(trimethylazaniumyl)phenoxycarbonyl]amino}decyl)carbamoyl]oxy}anilinium
NCGC00179526-05
benzenaminium, 3,3'-[1,10-decanediylbis[(methylimino)carbonyloxy]]bis[n,n,n-trimethyl-
3,3'-(1,10-decanediylbis((methylimino)carbonyloxy))bis(n,n,n-trimethylbenzenaminium)-
dtxcid501474526
n,n'-bis(3-trimethylammoniumphenoxycarbonyl)-n,n'-dimethyldecamethylenediamine
benzenaminium, 3,3'-(1,10-decanediylbis((methylimino)carbonyloxy))bis(n,n,n-trimethyl)-

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" Other antiglaucoma medications were administered with verapamil to determine their combined effect on intraocular pressure."( Effect of calcium channel blockers alone and in combination with antiglaucoma medications on intraocular pressure in the primate eye.
Erickson, KA; Netland, PA; Schroeder, A; Siegner, SW, 2000
)
0.31

Dosage Studied

ExcerptRelevanceReference
" Although DB/GB and betaxolol equally delayed or prevented the onset of glaucoma in the second eye, a less frequent dosing schedule for DB/GB suggests demecarium bromide in combination with a topical corticosteroid may be preferable to betaxolol in preventing PCAG in dogs."( The efficacy of topical prophylactic antiglaucoma therapy in primary closed angle glaucoma in dogs: a multicenter clinical trial.
Herrmann, MK; Miller, PE; Schmidt, GM; Swanson, JF; Vainisi, SJ,
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
quaternary ammonium ionA derivative of ammonium, NH4(+), in which all four of the hydrogens bonded to nitrogen have been replaced with univalent (usually organyl) groups.
carbamate esterAny ester of carbamic acid or its N-substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency18.99910.01237.983543.2770AID1645841
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-199026 (78.79)18.7374
1990's2 (6.06)18.2507
2000's3 (9.09)29.6817
2010's2 (6.06)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.27 (24.57)
Research Supply Index3.61 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index60.73 (26.88)
Search Engine Supply Index2.29 (0.95)

This Compound (38.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (5.88%)5.53%
Reviews1 (2.94%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other31 (91.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]